Reasons for Ineligibility in Phase 1 and 2A HIV Vaccine Clinical Trials at Kenya Aids Vaccine Initiative (KAVI), Kenya
2011

Reasons for Ineligibility in HIV Vaccine Trials in Kenya

Sample size: 281 publication Evidence: moderate

Author Information

Author(s): Omosa-Manyonyi Gloria S., Jaoko Walter, Anzala Omu, Ogutu Hilda, Wakasiaka Sabina, Malogo Roselyn, Nyange Jacqueline, Njuguna Pamela, Ndinya-Achola Jeckoniah, Bhatt Kirana, Farah Bashir, Oyaro Micah, Schmidt Claudia, Priddy Frances, Fast Patricia

Primary Institution: Kenya AIDS Vaccine Initiative (KAVI), University of Nairobi, Nairobi, Kenya

Hypothesis

What are the reasons for participant ineligibility in HIV vaccine clinical trials conducted in Kenya?

Conclusion

Over 61% of the screening exclusions in clinically healthy people were due to laboratory abnormalities.

Supporting Evidence

  • 281 participants were screened for two clinical trials.
  • 167 participants (59.4%) met the inclusion/exclusion criteria.
  • 61.4% of ineligibility was due to laboratory abnormalities.
  • 30.7% of ineligibility was due to medical abnormalities.
  • 18.6% of eligible participants declined enrolment.

Takeaway

When people wanted to join HIV vaccine trials, many were turned away because their lab tests showed problems. This means we need to use local lab standards to help more people join.

Methodology

Participants were screened for eligibility through medical history, physical examination, and laboratory testing.

Potential Biases

Potential bias due to reliance on non-local laboratory reference ranges for eligibility.

Limitations

The study did not include all possible endemic co-morbidities that could affect laboratory results.

Participant Demographics

Participants were aged 18 to 60, with a mix of males and females.

Digital Object Identifier (DOI)

10.1371/journal.pone.0014580

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication